VitaNova Life Sciences (VNOV) Accounts Payables (2023 - 2026)

VitaNova Life Sciences has disclosed Accounts Payables across 4 years of filings, most recently posting $122805.0 for Q3 2026.

• Accounts Payables for Q3 2026 came in at $122805.0, up 82.12% year-over-year; the trailing twelve-month figure through Jul 2026 was $122805.0 (up 82.12% YoY), and the FY2026 annual result was $208813.0, changed N/A from the prior year.
• Accounts Payables for Q3 2026 stood at $122805.0, down from $208813.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $208813.0 in Q2 2026 and bottomed at $51843.0 in Q2 2023.
• Average Accounts Payables over 4 years is $99787.4, with a median of $70778.0 recorded in 2024.
• On a YoY basis, Accounts Payables climbed as much as 142.81% in 2025 and fell as far as 0.27% in 2025.
• Year by year, Accounts Payables stood at $51843.0 in 2023, then soared by 33.82% to $69375.0 in 2024, then surged by 142.81% to $168450.0 in 2025, then dropped by 27.1% to $122805.0 in 2026.
• The last three Accounts Payables figures came in at $122805.0 (Q3 2026), $208813.0 (Q2 2026), and $108978.0 (Q1 2026), per Business Quant data.